why choose us

First received: April 06, 2023

Clinical Trial: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Parkinson Disease Psychosis

Study Type: INTERVENTIONAL


Official Title: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

Brief Summary: This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease.Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between.Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine…

Read more